1,148 Eli Lilly and Company $LLY Shares Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky trimmed its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 0.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,514 shares of the company’s stock after selling 1,148 shares during the period. Eli Lilly and Company accounts for approximately 1.2% of Teachers Retirement System of The State of Kentucky’s holdings, making the stock its 11th largest position. Teachers Retirement System of The State of Kentucky’s holdings in Eli Lilly and Company were worth $171,843,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Willow Creek Capital Management Inc. raised its stake in Eli Lilly and Company by 20.5% during the 3rd quarter. Willow Creek Capital Management Inc. now owns 676 shares of the company’s stock worth $782,000 after acquiring an additional 115 shares during the period. Warner Group LLC boosted its position in shares of Eli Lilly and Company by 9.9% in the third quarter. Warner Group LLC now owns 4,246 shares of the company’s stock worth $4,913,000 after purchasing an additional 383 shares during the period. Tilson Financial Group Inc. bought a new position in shares of Eli Lilly and Company in the third quarter worth approximately $248,000. Proactive Wealth Strategies LLC boosted its position in shares of Eli Lilly and Company by 1.3% in the third quarter. Proactive Wealth Strategies LLC now owns 9,798 shares of the company’s stock worth $11,351,000 after purchasing an additional 129 shares during the period. Finally, BCS Private Wealth Management Inc. increased its stake in shares of Eli Lilly and Company by 29.3% in the third quarter. BCS Private Wealth Management Inc. now owns 2,209 shares of the company’s stock worth $2,556,000 after purchasing an additional 500 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Recent Eli Lilly and Company Headlines

These are some of the LLY headlines that stood out recently:

  • Positive Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding experimental treatments for rare blood cancers—essential thrombocythemia and myelofibrosis—and broadening its portfolio beyond obesity drugs. The medicines are still in development, so their commercial potential is not yet established. Read article
  • Positive Sentiment: New ObesityWeek data covered Zepbound, Foundayo, EloraTZP, and retatrutide, with reported efficacy signals across weight loss and related conditions. The findings may support Lilly’s pipeline and future growth prospects. Read article
  • Positive Sentiment: Barclays raised its price target from $1,400 to $1,550 and maintained an “overweight” rating, signaling continued analyst confidence. Read article

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Guggenheim lifted their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Finally, Argus increased their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,422.00.

Get Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Trading Down 0.9%

LLY stock opened at $1,431.12 on Tuesday. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The company has a market capitalization of $1.35 trillion, a price-to-earnings ratio of 46.45, a PEG ratio of 1.71 and a beta of 0.40. The business has a 50 day simple moving average of $1,247.93 and a two-hundred day simple moving average of $1,112.33.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company’s revenue was up 38.6% on a year-over-year basis. During the same period last year, the firm posted $7.02 EPS. Research analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Read More

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.